|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.40 EUR | +0.42% |
|
-5.52% | +6.41% |
| 07-23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Eurofins Scientific: BioPharma's slowdown raises questions on 2026 organic growth target |  |
Company Valuation: Eurofins Scientific SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 20,893 | 12,900 | 11,336 | 9,273 | 11,036 | 11,527 | - | - |
| Change | - | -38.26% | -12.13% | -18.2% | 19.02% | 4.45% | - | - |
| Enterprise Value (EV) 1 | 23,132 | 15,739 | 14,041 | 12,269 | 14,677 | 14,807 | 14,621 | 14,249 |
| Change | - | -31.96% | -10.79% | -12.62% | 19.63% | 0.89% | -1.26% | -2.54% |
| P/E | 27.8x | 22.2x | 45.4x | 26.9x | 28x | 22.1x | 17.7x | 15.1x |
| PBR | 4.49x | 2.7x | 2.24x | 1.73x | 2.56x | 2.46x | 2.24x | 2.07x |
| PEG | - | -1x | -0.8x | 0.7x | 1.3x | 0.6x | 0.7x | 0.8x |
| Capitalization / Revenue | 3.11x | 1.92x | 1.74x | 1.33x | 1.51x | 1.52x | 1.43x | 1.34x |
| EV / Revenue | 3.44x | 2.34x | 2.16x | 1.77x | 2.01x | 1.95x | 1.82x | 1.66x |
| EV / EBITDA | 12.2x | 10.4x | 10.3x | 7.91x | 8.94x | 8.48x | 7.73x | 6.91x |
| EV / EBIT | 15.7x | 15.2x | 16.7x | 12.1x | 13.6x | 13.1x | 11.8x | 10.2x |
| EV / FCF | 22.8x | 23.2x | 29.6x | 15.3x | 16.7x | 16.6x | 17x | 14.7x |
| FCF Yield | 4.39% | 4.3% | 3.38% | 6.53% | 5.97% | 6.01% | 5.89% | 6.8% |
| Dividend per Share 2 | 1 | 1 | 0.5 | 0.5 | 0.72 | 0.7871 | 0.9 | 0.9494 |
| Rate of return | 0.92% | 1.49% | 0.85% | 1.01% | 1.15% | 1.19% | 1.36% | 1.43% |
| EPS 2 | 3.91 | 3.02 | 1.3 | 1.83 | 2.23 | 3.002 | 3.743 | 4.41 |
| Distribution rate | 25.6% | 33.1% | 38.5% | 27.3% | 32.3% | 26.2% | 24% | 21.5% |
| Net sales 1 | 6,718 | 6,712 | 6,515 | 6,951 | 7,296 | 7,589 | 8,046 | 8,605 |
| EBITDA 1 | 1,902 | 1,513 | 1,364 | 1,552 | 1,641 | 1,746 | 1,892 | 2,062 |
| EBIT 1 | 1,473 | 1,037 | 842 | 1,017 | 1,079 | 1,131 | 1,243 | 1,395 |
| Net income 1 | 783 | 606 | 310 | 406 | 475 | 541.9 | 667.7 | 796.3 |
| Net Debt 1 | 2,239 | 2,839 | 2,705 | 2,996 | 3,641 | 3,280 | 3,094 | 2,722 |
| Reference price 2 | 108.80 | 67.06 | 58.98 | 49.31 | 62.40 | 66.40 | 66.40 | 66.40 |
| Nbr of stocks (in thousands) | 192,035 | 192,365 | 192,194 | 188,049 | 176,864 | 173,599 | - | - |
| Announcement Date | 2/22/22 | 3/1/23 | 2/27/24 | 1/30/25 | 1/29/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.12x | 1.95x | 8.48x | 1.19% | 13.12B | |
| 32.25x | 5.76x | 17.3x | 1.02% | 46.86B | |
| -23.62x | 354.58x | -21.66x | -.--% | 40.23B | |
| 48.91x | 4.94x | 31.87x | -.--% | 36.23B | |
| 25.32x | 2.8x | 12.1x | -.--% | 34.72B | |
| 27.42x | 8.04x | 20.17x | 0.41% | 27.89B | |
| 34.31x | 5.61x | 25.58x | -.--% | 16.79B | |
| 23.43x | 1.87x | 11.34x | -.--% | 12.7B | |
| 61.46x | 9.18x | 26.07x | 0.45% | 11.16B | |
| Average | 27.95x | 43.86x | 14.58x | 0.34% | 26.63B | |
| Weighted average by Cap. | 24.31x | 63.75x | 12.73x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ERF Stock
- Valuation Eurofins Scientific SE
Select your edition
All financial news and data tailored to specific country editions
